A comparison of the cost-effectiveness of treatment of prolonged acute convulsive epileptic seizures in children across Europe

In the majority of children and adolescents with epilepsy, optimal drug therapy adequately controls their condition. However, among the remaining patients who are still uncontrolled despite mono-, bi- or tri-therapy with chronic anti-epileptic treatment, a rescue medication is required. In Western E...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Health economics review 2014-01, Vol.4 (6), p.1-15, Article 6
Hauptverfasser: Lee, Dawn C, Gladwell, Daniel, Hatswell, Anthony J, Porter, Joshua, Brereton, Nic, Tate, Elaine, Saunders, Alison, L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 15
container_issue 6
container_start_page 1
container_title Health economics review
container_volume 4
creator Lee, Dawn C
Gladwell, Daniel
Hatswell, Anthony J
Porter, Joshua
Brereton, Nic
Tate, Elaine
Saunders, Alison, L
description In the majority of children and adolescents with epilepsy, optimal drug therapy adequately controls their condition. However, among the remaining patients who are still uncontrolled despite mono-, bi- or tri-therapy with chronic anti-epileptic treatment, a rescue medication is required. In Western Europe, the licensed medications available for first-line treatment of prolonged acute convulsive seizures (PACS) vary widely, and so comparators for clinical and economic evaluation are not consistent. No European guidelines currently exist for the treatment of PACS in children and adolescents and limited evidence is available for the effectiveness of treatments in the community setting. The authors present cost-effectiveness data for BUCCOLAM® (midazolam oromucosal solution) for the treatment of PACS in children and adolescents in the context of the treatment pathway in seven European countries in patients from 6 months to 18 years. For each country, the health economic model consisted of a decision tree, with decision nodes informed by clinical data and expert opinion obtained via a Delphi methodology. The events modelled are those associated with a patient experiencing a seizure in the community setting. The model assessed the likelihood of medication being administered successfully and of seizure cessation. The associated resource use was also modelled, and ambulance call-outs and hospitalisations were considered. The patient's quality of life was estimated by clinicians, who completed a five-level EuroQol five dimensions questionnaire from the perspective of a child or adolescent suffering a seizure. Despite differences in current therapy, treatment patterns and healthcare costs in all countries assessed, BUCCOLAM was shown to be cost saving and offered increased health-related benefits for patients in the treatment of PACS compared with the current local standard of care.
doi_str_mv 10.1186/s13561-014-0006-6
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4052771</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1539474849</sourcerecordid><originalsourceid>FETCH-LOGICAL-b608t-4d833b1b97450aa5ebe4e5c4409af4244b8fc80d7c1d2f5d2d67a0297164376a3</originalsourceid><addsrcrecordid>eNp9kk9v1DAQxSMEolXpB-AAROLCJeBxHDu-IFWl_JEqcYGz5TiTrqusHWxnJTjw2XGastpFwMlJ5ueXN2-mKJ4CeQ3Q8jcR6oZDRYBVhBBe8QfFKQUJFUgJDw-eT4rzGG_JAjVAG_G4OKFMMklbclr8vCiN30462Ohd6YcybTB_ianCYUCT7A4dxnhXCajTFl1aXqbgR-9usC-1mdNyxe3mMWa8xMmOOCVryoj2xxwwltaVZmPHPqDLfPBZ8GoOfsInxaNBjxHP78-z4uv7qy-XH6vrzx8-XV5cVx0nbapY39Z1B50UrCFaN9ghw8YwRqQeGGWsawfTkl4Y6OnQ9LTnQhMqBXBWC67rs-LtqjvN3RZ7k7sIelRTsFsdviuvrTquOLtRN36nGGmoEJAF3q0CnfX_EDiu5FTVOiKVR6SW9BXPMq_ufQT_bcaY1NZGg-OoHfo5KmhqyQRrmczoyz_QWz8Hl1NSIOrcGMiWZApW6i7VgMPeEhC17MlfTTw_DGN_4_dWZODFCmAeq417oKU8awm6mKMrEXMtr0E4MPef_z47kl2OmHzIXRPGaf0LlcTfiw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1731641980</pqid></control><display><type>article</type><title>A comparison of the cost-effectiveness of treatment of prolonged acute convulsive epileptic seizures in children across Europe</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SpringerNature Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>PubMed Central</source><creator>Lee, Dawn C ; Gladwell, Daniel ; Hatswell, Anthony J ; Porter, Joshua ; Brereton, Nic ; Tate, Elaine ; Saunders, Alison, L</creator><creatorcontrib>Lee, Dawn C ; Gladwell, Daniel ; Hatswell, Anthony J ; Porter, Joshua ; Brereton, Nic ; Tate, Elaine ; Saunders, Alison, L</creatorcontrib><description>In the majority of children and adolescents with epilepsy, optimal drug therapy adequately controls their condition. However, among the remaining patients who are still uncontrolled despite mono-, bi- or tri-therapy with chronic anti-epileptic treatment, a rescue medication is required. In Western Europe, the licensed medications available for first-line treatment of prolonged acute convulsive seizures (PACS) vary widely, and so comparators for clinical and economic evaluation are not consistent. No European guidelines currently exist for the treatment of PACS in children and adolescents and limited evidence is available for the effectiveness of treatments in the community setting. The authors present cost-effectiveness data for BUCCOLAM® (midazolam oromucosal solution) for the treatment of PACS in children and adolescents in the context of the treatment pathway in seven European countries in patients from 6 months to 18 years. For each country, the health economic model consisted of a decision tree, with decision nodes informed by clinical data and expert opinion obtained via a Delphi methodology. The events modelled are those associated with a patient experiencing a seizure in the community setting. The model assessed the likelihood of medication being administered successfully and of seizure cessation. The associated resource use was also modelled, and ambulance call-outs and hospitalisations were considered. The patient's quality of life was estimated by clinicians, who completed a five-level EuroQol five dimensions questionnaire from the perspective of a child or adolescent suffering a seizure. Despite differences in current therapy, treatment patterns and healthcare costs in all countries assessed, BUCCOLAM was shown to be cost saving and offered increased health-related benefits for patients in the treatment of PACS compared with the current local standard of care.</description><identifier>ISSN: 2191-1991</identifier><identifier>EISSN: 2191-1991</identifier><identifier>DOI: 10.1186/s13561-014-0006-6</identifier><identifier>PMID: 24949280</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>BUCCOLAM ; Caregivers ; Childrens health ; Convulsions &amp; seizures ; Cost analysis ; Cost–utility modelling ; Drug resistance ; Drug therapy ; Economic models ; Economic statistics ; Economic theory ; Epilepsy ; Guidelines ; Health care ; Health Care Management ; Health Economics ; Health Services Research ; Health technology assessment ; Licenses ; Medicine ; Medicine &amp; Public Health ; Patients ; Pediatrics ; Pharmacoeconomics and Health Outcomes ; Prescription drugs ; Public Finance ; Public Health ; Studies ; Teenagers</subject><ispartof>Health economics review, 2014-01, Vol.4 (6), p.1-15, Article 6</ispartof><rights>Lee et al.; licensee Springer. 2014. This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>The Author(s) 2014</rights><rights>Copyright © 2014 Lee et al.; licensee Springer 2014 Lee et al.; licensee Springer</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b608t-4d833b1b97450aa5ebe4e5c4409af4244b8fc80d7c1d2f5d2d67a0297164376a3</citedby><cites>FETCH-LOGICAL-b608t-4d833b1b97450aa5ebe4e5c4409af4244b8fc80d7c1d2f5d2d67a0297164376a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052771/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052771/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,41120,41488,42189,42557,51319,51576,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24949280$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Dawn C</creatorcontrib><creatorcontrib>Gladwell, Daniel</creatorcontrib><creatorcontrib>Hatswell, Anthony J</creatorcontrib><creatorcontrib>Porter, Joshua</creatorcontrib><creatorcontrib>Brereton, Nic</creatorcontrib><creatorcontrib>Tate, Elaine</creatorcontrib><creatorcontrib>Saunders, Alison, L</creatorcontrib><title>A comparison of the cost-effectiveness of treatment of prolonged acute convulsive epileptic seizures in children across Europe</title><title>Health economics review</title><addtitle>Health Econ Rev</addtitle><addtitle>Health Econ Rev</addtitle><description>In the majority of children and adolescents with epilepsy, optimal drug therapy adequately controls their condition. However, among the remaining patients who are still uncontrolled despite mono-, bi- or tri-therapy with chronic anti-epileptic treatment, a rescue medication is required. In Western Europe, the licensed medications available for first-line treatment of prolonged acute convulsive seizures (PACS) vary widely, and so comparators for clinical and economic evaluation are not consistent. No European guidelines currently exist for the treatment of PACS in children and adolescents and limited evidence is available for the effectiveness of treatments in the community setting. The authors present cost-effectiveness data for BUCCOLAM® (midazolam oromucosal solution) for the treatment of PACS in children and adolescents in the context of the treatment pathway in seven European countries in patients from 6 months to 18 years. For each country, the health economic model consisted of a decision tree, with decision nodes informed by clinical data and expert opinion obtained via a Delphi methodology. The events modelled are those associated with a patient experiencing a seizure in the community setting. The model assessed the likelihood of medication being administered successfully and of seizure cessation. The associated resource use was also modelled, and ambulance call-outs and hospitalisations were considered. The patient's quality of life was estimated by clinicians, who completed a five-level EuroQol five dimensions questionnaire from the perspective of a child or adolescent suffering a seizure. Despite differences in current therapy, treatment patterns and healthcare costs in all countries assessed, BUCCOLAM was shown to be cost saving and offered increased health-related benefits for patients in the treatment of PACS compared with the current local standard of care.</description><subject>BUCCOLAM</subject><subject>Caregivers</subject><subject>Childrens health</subject><subject>Convulsions &amp; seizures</subject><subject>Cost analysis</subject><subject>Cost–utility modelling</subject><subject>Drug resistance</subject><subject>Drug therapy</subject><subject>Economic models</subject><subject>Economic statistics</subject><subject>Economic theory</subject><subject>Epilepsy</subject><subject>Guidelines</subject><subject>Health care</subject><subject>Health Care Management</subject><subject>Health Economics</subject><subject>Health Services Research</subject><subject>Health technology assessment</subject><subject>Licenses</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Pharmacoeconomics and Health Outcomes</subject><subject>Prescription drugs</subject><subject>Public Finance</subject><subject>Public Health</subject><subject>Studies</subject><subject>Teenagers</subject><issn>2191-1991</issn><issn>2191-1991</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp9kk9v1DAQxSMEolXpB-AAROLCJeBxHDu-IFWl_JEqcYGz5TiTrqusHWxnJTjw2XGastpFwMlJ5ueXN2-mKJ4CeQ3Q8jcR6oZDRYBVhBBe8QfFKQUJFUgJDw-eT4rzGG_JAjVAG_G4OKFMMklbclr8vCiN30462Ohd6YcybTB_ianCYUCT7A4dxnhXCajTFl1aXqbgR-9usC-1mdNyxe3mMWa8xMmOOCVryoj2xxwwltaVZmPHPqDLfPBZ8GoOfsInxaNBjxHP78-z4uv7qy-XH6vrzx8-XV5cVx0nbapY39Z1B50UrCFaN9ghw8YwRqQeGGWsawfTkl4Y6OnQ9LTnQhMqBXBWC67rs-LtqjvN3RZ7k7sIelRTsFsdviuvrTquOLtRN36nGGmoEJAF3q0CnfX_EDiu5FTVOiKVR6SW9BXPMq_ufQT_bcaY1NZGg-OoHfo5KmhqyQRrmczoyz_QWz8Hl1NSIOrcGMiWZApW6i7VgMPeEhC17MlfTTw_DGN_4_dWZODFCmAeq417oKU8awm6mKMrEXMtr0E4MPef_z47kl2OmHzIXRPGaf0LlcTfiw</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Lee, Dawn C</creator><creator>Gladwell, Daniel</creator><creator>Hatswell, Anthony J</creator><creator>Porter, Joshua</creator><creator>Brereton, Nic</creator><creator>Tate, Elaine</creator><creator>Saunders, Alison, L</creator><general>Springer</general><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><general>BioMed Central Ltd</general><scope>OT2</scope><scope>C6C</scope><scope>OQ6</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7WY</scope><scope>7WZ</scope><scope>7XB</scope><scope>87Z</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>F~G</scope><scope>K60</scope><scope>K6~</scope><scope>L.-</scope><scope>M0C</scope><scope>PIMPY</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140101</creationdate><title>A comparison of the cost-effectiveness of treatment of prolonged acute convulsive epileptic seizures in children across Europe</title><author>Lee, Dawn C ; Gladwell, Daniel ; Hatswell, Anthony J ; Porter, Joshua ; Brereton, Nic ; Tate, Elaine ; Saunders, Alison, L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b608t-4d833b1b97450aa5ebe4e5c4409af4244b8fc80d7c1d2f5d2d67a0297164376a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>BUCCOLAM</topic><topic>Caregivers</topic><topic>Childrens health</topic><topic>Convulsions &amp; seizures</topic><topic>Cost analysis</topic><topic>Cost–utility modelling</topic><topic>Drug resistance</topic><topic>Drug therapy</topic><topic>Economic models</topic><topic>Economic statistics</topic><topic>Economic theory</topic><topic>Epilepsy</topic><topic>Guidelines</topic><topic>Health care</topic><topic>Health Care Management</topic><topic>Health Economics</topic><topic>Health Services Research</topic><topic>Health technology assessment</topic><topic>Licenses</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Pharmacoeconomics and Health Outcomes</topic><topic>Prescription drugs</topic><topic>Public Finance</topic><topic>Public Health</topic><topic>Studies</topic><topic>Teenagers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Dawn C</creatorcontrib><creatorcontrib>Gladwell, Daniel</creatorcontrib><creatorcontrib>Hatswell, Anthony J</creatorcontrib><creatorcontrib>Porter, Joshua</creatorcontrib><creatorcontrib>Brereton, Nic</creatorcontrib><creatorcontrib>Tate, Elaine</creatorcontrib><creatorcontrib>Saunders, Alison, L</creatorcontrib><collection>EconStor</collection><collection>Springer Nature OA Free Journals</collection><collection>ECONIS</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Access via ABI/INFORM (ProQuest)</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Global</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Health economics review</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Dawn C</au><au>Gladwell, Daniel</au><au>Hatswell, Anthony J</au><au>Porter, Joshua</au><au>Brereton, Nic</au><au>Tate, Elaine</au><au>Saunders, Alison, L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A comparison of the cost-effectiveness of treatment of prolonged acute convulsive epileptic seizures in children across Europe</atitle><jtitle>Health economics review</jtitle><stitle>Health Econ Rev</stitle><addtitle>Health Econ Rev</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>4</volume><issue>6</issue><spage>1</spage><epage>15</epage><pages>1-15</pages><artnum>6</artnum><issn>2191-1991</issn><eissn>2191-1991</eissn><abstract>In the majority of children and adolescents with epilepsy, optimal drug therapy adequately controls their condition. However, among the remaining patients who are still uncontrolled despite mono-, bi- or tri-therapy with chronic anti-epileptic treatment, a rescue medication is required. In Western Europe, the licensed medications available for first-line treatment of prolonged acute convulsive seizures (PACS) vary widely, and so comparators for clinical and economic evaluation are not consistent. No European guidelines currently exist for the treatment of PACS in children and adolescents and limited evidence is available for the effectiveness of treatments in the community setting. The authors present cost-effectiveness data for BUCCOLAM® (midazolam oromucosal solution) for the treatment of PACS in children and adolescents in the context of the treatment pathway in seven European countries in patients from 6 months to 18 years. For each country, the health economic model consisted of a decision tree, with decision nodes informed by clinical data and expert opinion obtained via a Delphi methodology. The events modelled are those associated with a patient experiencing a seizure in the community setting. The model assessed the likelihood of medication being administered successfully and of seizure cessation. The associated resource use was also modelled, and ambulance call-outs and hospitalisations were considered. The patient's quality of life was estimated by clinicians, who completed a five-level EuroQol five dimensions questionnaire from the perspective of a child or adolescent suffering a seizure. Despite differences in current therapy, treatment patterns and healthcare costs in all countries assessed, BUCCOLAM was shown to be cost saving and offered increased health-related benefits for patients in the treatment of PACS compared with the current local standard of care.</abstract><cop>Heidelberg</cop><pub>Springer</pub><pmid>24949280</pmid><doi>10.1186/s13561-014-0006-6</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2191-1991
ispartof Health economics review, 2014-01, Vol.4 (6), p.1-15, Article 6
issn 2191-1991
2191-1991
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4052771
source DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SpringerNature Journals; PubMed Central Open Access; Springer Nature OA Free Journals; PubMed Central
subjects BUCCOLAM
Caregivers
Childrens health
Convulsions & seizures
Cost analysis
Cost–utility modelling
Drug resistance
Drug therapy
Economic models
Economic statistics
Economic theory
Epilepsy
Guidelines
Health care
Health Care Management
Health Economics
Health Services Research
Health technology assessment
Licenses
Medicine
Medicine & Public Health
Patients
Pediatrics
Pharmacoeconomics and Health Outcomes
Prescription drugs
Public Finance
Public Health
Studies
Teenagers
title A comparison of the cost-effectiveness of treatment of prolonged acute convulsive epileptic seizures in children across Europe
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T01%3A50%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20comparison%20of%20the%20cost-effectiveness%20of%20treatment%20of%20prolonged%20acute%20convulsive%20epileptic%20seizures%20in%20children%20across%20Europe&rft.jtitle=Health%20economics%20review&rft.au=Lee,%20Dawn%20C&rft.date=2014-01-01&rft.volume=4&rft.issue=6&rft.spage=1&rft.epage=15&rft.pages=1-15&rft.artnum=6&rft.issn=2191-1991&rft.eissn=2191-1991&rft_id=info:doi/10.1186/s13561-014-0006-6&rft_dat=%3Cproquest_pubme%3E1539474849%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1731641980&rft_id=info:pmid/24949280&rfr_iscdi=true